186 related articles for article (PubMed ID: 4146168)
1. Induction of unresponsiveness to skin and heart allografts in mice by a synergistic treatment with procarbazine, antilymphocyte serum, and donor-type cells.
Floersheim GL
Transplantation; 1973 Feb; 15(2):195-205. PubMed ID: 4146168
[No Abstract] [Full Text] [Related]
2. The effect of cyclophosphamide on the splecific unresponsiveness to skin allografts induced in ALS-treated mice infused with donor bone marrow.
Wood ML; Monaco AP
J Immunol; 1977 Apr; 118(4):1456-9. PubMed ID: 321691
[TBL] [Abstract][Full Text] [Related]
3. Active enhancement of tissue allografts with antilymphocyte serum and bone marrow.
Monaco AP; Liegeois A; Wood ML; Clark AW
Adv Nephrol Necker Hosp; 1975; 5():135-72. PubMed ID: 242206
[No Abstract] [Full Text] [Related]
4. Specific unresponsiveness to skin allografts in mice. V. Synergy between donor tissue extract, procarbazine hydrochloride, and antilymphocyte serum in creating a long-lasting unresponsiveness mediated by suppressor T cells.
Brent L; Opara SC
Transplantation; 1979 Feb; 27(2):120-6. PubMed ID: 380069
[No Abstract] [Full Text] [Related]
5. Models of specific unresponsiveness to tissue allografts in antilymphocyte serum (ALS) treated mice.
Wood ML; Monaco AP
Transplant Proc; 1978 Jun; 10(2):379-87. PubMed ID: 354127
[No Abstract] [Full Text] [Related]
6. Adaptive phenomena in bone marrow transplantation.
Goujet-Zalc C; Ilbery PL
Exp Hematol; 1973; 1(1):3-10. PubMed ID: 4154047
[No Abstract] [Full Text] [Related]
7. Unresponsiveness to rat cardiac allografts induced by intrathymic injection of donor bone marrow cells and short course of immunosuppression.
Hara Y; Matsuura T; Imanishi M; Tahara H; Kurita T
Transplant Proc; 1994 Dec; 26(6):3226-8. PubMed ID: 7527955
[No Abstract] [Full Text] [Related]
8. Letter: Increasing the efficacy of antilymphocyte globulin.
Floersheim GL
Lancet; 1973 Dec; 2(7842):1386-7. PubMed ID: 4128075
[No Abstract] [Full Text] [Related]
9. Efficacy of a cyclophosphamide-procarbazine-antithymocyte serum regimen for prevention of graft rejection following bone marrow transplantation for transfused patients with aplastic anemia.
Smith BR; Guinan EC; Parkman R; Ferrara J; Levey RH; Nathan DG; Rappeport JM
Transplantation; 1985 Jun; 39(6):671-3. PubMed ID: 3890295
[No Abstract] [Full Text] [Related]
10. Pretreatment with antilymphocyte globulin and donor cells on graft prolongation in an experimental model and some observations on graft-versus-host reaction.
Pegrum GD; Williams G; Markwick J; Barnes RM
Postgrad Med J; 1976; 52(5 Suppl):47-50. PubMed ID: 11454
[TBL] [Abstract][Full Text] [Related]
11. The role of donor passenger leukocytes in rat skin allograft rejection.
Kyger ER; Salyer KE
Transplantation; 1973 Dec; 16(6):537-43. PubMed ID: 4585381
[No Abstract] [Full Text] [Related]
12. Use of antilymphocyte serum and bone marrow for production of immunological tolerance and enhancement: review and recent experiments.
Wood ML; Gozzo JJ; Monaco AP
Transplant Proc; 1972 Dec; 4(4):523-9. PubMed ID: 4405146
[No Abstract] [Full Text] [Related]
13. "In vivo" standardization model for defining the dose-response-dependent graft-protective value of antilymphocyte sera.
Réthy L; Osz E
Dev Biol Stand; 1974; 27():233-5. PubMed ID: 4618536
[No Abstract] [Full Text] [Related]
14. Transplantation of the mouse heart--a useful research model.
Jirsch DW; Kraft N; Diener E
Cardiovasc Res; 1974 Jan; 8(1):145-8. PubMed ID: 4150497
[No Abstract] [Full Text] [Related]
15. Syngeneic bone marrow expressing a single donor class I MHC molecule permits acceptance of a fully allogeneic cardiac allograft.
Wong W; Morris PJ; Wood KJ
Transplantation; 1996 Nov; 62(10):1462-8. PubMed ID: 8958273
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hyperacute graft-versus-host disease in mice with cytosine arabinoside.
Floersheim GL
Transplantation; 1972 Sep; 14(3):325-30. PubMed ID: 4404693
[No Abstract] [Full Text] [Related]
17. Antilymphocytic antibodies and marrow transplantation. IV. Comparison of the effects of antibody fragments directed against immunoglobulin or lymphocyte antigens on acute secondary disease.
Rodt H; Therfelder S; Eulitz M
Exp Hematol; 1974; 2(4):195-203. PubMed ID: 4156327
[No Abstract] [Full Text] [Related]
18. [Prevention of the graft vs host reaction in rats by means of allogeneic antilymphocyte serum following bone marrow transplantation].
Jeannet M; Vaucher A; Gervasoni C
Schweiz Med Wochenschr; 1972 Nov; 102(44):1598-600. PubMed ID: 4405059
[No Abstract] [Full Text] [Related]
19. Use of allogenic, homozygous bone marrow cells for the induction of specific immunologic tolerance in mice treated with antilymphocyte serum.
Gozzo JJ; Wood ML; Monaco AP
Surg Forum; 1970; 21():281-4. PubMed ID: 4936984
[No Abstract] [Full Text] [Related]
20. Bone marrow transplantation in the busulfin-treated rat. III. Relationship between myelosuppression and immunosuppression for conditioning bone marrow recipients.
Tutschka PJ; Santon GW
Transplantation; 1977 Jul; 24(1):52-62. PubMed ID: 18820
[No Abstract] [Full Text] [Related]
[Next] [New Search]
